Evoke Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Evoke Pharma şirketinin toplam hissedar öz sermayesi $2.7M ve toplam borcu $5.0M olup, bu da borç-öz sermaye oranını 187.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $12.1M ve $9.5M dir.

Anahtar bilgiler

187.6%

Borç/özkaynak oranı

US$5.00m

Borç

Faiz karşılama oranı	n/a
Nakit	US$9.18m
Eşitlik	US$2.66m
Toplam yükümlülükler	US$9.47m
Toplam varlıklar	US$12.14m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EV0 'nin kısa vadeli varlıkları ( $12.1M ) kısa vadeli yükümlülüklerini ( $9.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: EV0 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EV0 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: EV0 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 187.6% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EV0 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: EV0 serbest nakit akışı her yıl % { 0.9 1.5 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

Evoke Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Recent updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.67 loss in 1Q 2023)

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.60 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.62 loss per share (vs US$3.18 loss in FY 2021)

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.73 loss in 3Q 2021)

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.85 loss in 2Q 2021)

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis

Independent Director has left the company

No longer forecast to breakeven

Revenue misses expectations

Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €2.00

Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

Evoke Pharma, Inc. Announces, Through its Marketing Partner, Eversana Life Science Services, LLC, Conducted an ATU (Awareness, Trial, and Usage) Study, Quantitative Survey to Measure Physician Awareness, Trial, and Product Usage, for GIMOTI

New 90-day low: €2.07

Co-Founder recently sold €173k worth of stock

New 90-day low: €2.37

New 90-day low: €2.70

New 90-day low: €3.26

Evoke Pharma, Inc. and Eversana Life Science Services, LLC Announce Commercial Launch of Gimoti™

New 90-day high - €3.60

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço